Medifast enters medically supported weight loss market with $20M LifeMD deal; ends quarterly dividend

MEDIFAST INC

Medifast commits $20M to LifeMD ($10M platform contributions, $10M stock purchase) for collaboration.
Discontinues quarterly cash dividend immediately to redirect capital to technology and growth initiatives.
Launches OPTAVIA Nutrition Kit and Muscle Health Kit for medically supported weight loss patients.
Medifast cites medically supported weight loss market projected up to $100B by 2030 as rationale.
Collaboration integrates OPTAVIA coaches with LifeMD board-certified clinicians; pilot program completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.